(NASDAQ: NVAX) shares have brought investors extremely good times and extremely bad times. They soared back in 2020 on hopes the biotech would score a win with its coronavirus vaccine candidate. But as Novavax fell behind in the race, the stock retreated.

Since then, Novavax has launched a vaccine, but the late-to-market entry meant it missed out on the biggest revenue opportunity. After all, vaccine demand is on the decline as we head toward a post-pandemic situation.

But that isn't holding back Wall Street's optimism about Novavax's stock performance potential. The average analyst forecast calls for a 150% increase over the coming 12 months.

Continue reading

Source Fool.com